1. Home
  2. NWGL vs MAIA Comparison

NWGL vs MAIA Comparison

Compare NWGL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nature Wood Group Limited

NWGL

Nature Wood Group Limited

N/A

Current Price

$0.06

Market Cap

66.1M

Sector

N/A

ML Signal

N/A

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

N/A

Current Price

$1.09

Market Cap

69.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NWGL
MAIA
Founded
2008
2018
Country
Macau
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.1M
69.2M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
NWGL
MAIA
Price
$0.06
$1.09
Analyst Decision
Analyst Count
0
0
Target Price
N/A
★ $12.00
AVG Volume (30 Days)
★ 26.8M
310.8K
Earning Date
04-27-2026
11-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 33.33
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.06
$0.87
52 Week High
$1.98
$3.19

Technical Indicators

Market Signals
Indicator
NWGL
MAIA
Relative Strength Index (RSI) 25.06 45.16
Support Level N/A N/A
Resistance Level $0.34 $1.47
Average True Range (ATR) 0.07 0.06
MACD -0.01 0.01
Stochastic Oscillator 0.35 43.69

Price Performance

Historical Comparison
NWGL
MAIA

About NWGL Nature Wood Group Limited

CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: